Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.
$255.63+0.35%
报价 2026-11-06
市值
$28.21B
EV
$31.36B
PE (TTM)
24.3x
预期 PE (FY2026)
22.6x
52 周区间距高点 -0.0%
$173.49$255.68
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✗ Cheap✓ GARP
GARP Pool: growth 10-30%, MC/GP <= 11
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 11.04 → 11.98（1.1x） | 21.3 |
| FY+32028-12 | 1.1x | 11.04 → 13.06（1.2x） | 19.6 |
毛利率 33% · TTM 收入 $11841M · 基数 EPS 11.04（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DGXQuest Diagnostics Incorporated | $28.21B | +0.3% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| ILMNIllumina, Inc. | $32.23B | +2.5% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| LHLabcorp Holdings Inc. | $29.77B | +0.9% | +5.9% | 29.8% | 27.6x | 15.9x | 23.9x | |
| WSTWest Pharmaceutical Services, Inc. | $27.85B | +1.9% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| INCYIncyte Corporation | $24.39B | +1.4% | +12.9% | 91.8% | 13.9x | 8.5x | 17.9x | |
| UTHRUnited Therapeutics Corporation | $24.11B | -0.7% | +1.9% | 86.1% | 17.9x | 12.8x | 21.0x | |
| THCTenet Healthcare Corporation | $22.55B | -1.1% | +4.8% | 62.5% | 8.2x | 5.6x | 6.8x | Cheap |
| ZBHZimmer Biomet Holdings, Inc. | $20.14B | -1.2% | +4.7% | 71.2% | 26.6x | 11.9x | 12.2x | |
| 同行中位数 | – | – | +6.8% | 64.5% | 27.1x | 14.4x | 22.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.9B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B |
| Gross Margin | 33.7% | 32.5% | 32.6% | 33.7% | 34.2% | 32.5% | 32.7% | 32.6% |
| Operating Margin | 15.1% | 13.8% | 13.9% | 13.7% | 15.9% | 13% | 13.8% | 13.3% |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M |
| Diluted EPS | 2.84 | 2.24 | 2.18 | 2.16 | 2.47 | 1.94 | 1.95 | 1.99 |
| Operating Cash Flow | $468M | $278M | $465M | $563M | $544M | $314M | $464M | $356M |